Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HSRYV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DM005
|
|||||
| Synonyms |
DM005; YH013
Click to Show/Hide
|
|||||
| Organization |
Biocytogen (Originator);Duoma Biopharma
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-EGFR/c-Met bsAb
|
Antibody Info | ||||
| Antigen Name |
Hepatocyte growth factor receptor (MET); Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
BCPT02
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Hydrophilic, protease-cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
BLD1102
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion criteria: signed consent; age ≥18; advanced/metastatic solid tumors (NSCLC, gastroesophageal/colorectal/HCC/pancreatic/HNSCC) refractory to standard therapy; ECOG 0-2; life expectancy ≥3 months; measurable disease (RECIST 1.1).
|
||||
| Administration Dosage |
An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W, 0.5, 1, 2, 4, 6, 8 mg/kg.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06515990 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, Multicenter, Open-label, First-in-human, Dose Escalation and Expansion Study of DM005 in Patients With Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary endpoints include DLT incidence (grade 3 neurological/grade 4 toxicities) and MTD determination (0/3 or 1/6 DLT rate) for DM005 over 12 months.
|
||||
| Other Endpoint |
Secondary endpoints comprise PK parameters (AUC, Cmax, Tmax, Ctrough) and ORR assessment (RECIST v1.1) within 12 months.
|
||||